Provided By GlobeNewswire
Last update: Apr 16, 2025
SUNRISE-PD evaluating the Company’s anti-inflammatory, insulin-sensitizing candidate bezisterim in patients with Parkinson’s disease who have not been treated with carbidopa/levodopa
Read more at globenewswire.com